Latest Avastin Stories
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
CAMBRIDGE, Mass., Feb.
Reportbuyer.com just published a new market research report:
- An armed gangster.